Company intelligence / Profile preview

QXMédical

Montreal, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

QXMédical designs and commercially supplies minimally invasive catheters and embolic agents for coronary, peripheral and endovascular procedures. It is developing bioresorbable, drug‑loadable embolic microspheres and hydrogels licensed from the University of Minnesota, which have shown promising pre‑clinical performance comparable to permanent embolics with added benefits of bioresorption and drug loadability[1][2].

Therapeutic areas: HematologyOtherWomen's HealthCardiovascularOncologyMen's Health
Modalities: DeviceHydrogel-based drug delivery therapyNanoparticle
Industry: Surgical Medical Devices

Partnerships

University of Minnesota (license of bioresorbable embolic technology)

Beyond the preview

Go deeper on QXMédical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QXMédical.

Explore the full profile